M-Care - Mobilizing Migrant Communities via Capacity and Access Resource Development is a training programme that is jointly organised by the European AIDS Treatment Group (EATG) and the European African Treatment Advocates Network (EATAN). The training took place in Brussels, on 10-14 November 2016.
About M-Care Programme:
The four-day training is intended for advocates and treatment activists from migrant communities in Europe, with specific focus on sub-Saharan African communities, who are keen to make a difference by contributing to a stronger involvement of migrant communities in research, access programs, and early testing initiatives; as well as to fight HIV, HCV, and TB related stigma and discrimination towards and within their community, which will lead to an enhanced quality of life for migrants living in Europe.
Topics addressed during the training will be prevalence, pathology and treatment of HIV, HCV and TB among migrant communities in Europe; specific barriers to prevention, testing, treatment and care experienced by the community together with approaches to overcome them. Furthermore the training will address clinical research and doctor-patient relationship from the perspective of the various needs and challenges present within BME migrant communities in Europe. The last day of the training will be dedicated to patient advocacy – providing the participants with hands-on skills in working with stakeholders, as well as designing and delivering strategies for successful advocacy.
Following the training participants will be given the opportunity to apply for a scheme of follow-up grants to implement projects in their local community thus actively applying the knowledge and skills acquired throughout the M-Care training to support the quality of life of migrants living in Europe.
News about M-CARE
This initiative has been independently developed by EATG and EATAN, and was made possible through sponsorship from Bristol-Myers Squibb, MSD and Gilead Sciences Europe Ltd. EATG and EATAN acknowledge that Bristol-Myers Squibb, MSD and Gilead Sciences Europe Ltd. have not had any control or input into the structure or content of the initiative.